INSIDE THE LAB / THE LEDGER
Four Peptides, Four Different Places on the Evidence Ladder
Same reporting standard applied to all four: what was tested, in what model, and how far the finding can honestly travel.
The short version
Lined up together, ipamorelin, KPV, MOTS-c and tirzepatide look less like four flavors of the same thing and more like four snapshots taken at different stages of the same process — the process by which a molecule goes from a cell-culture curiosity to (in one case) an approved medicine. KPV has never left the lab bench. Ipamorelin got one shot at a human trial and the numbers came up short. MOTS-c has excellent mouse data and one human biomarker study, but no interventional human trial. Tirzepatide is the only one that made it all the way through Phase 3 and out the other side. None of this is a ranking of which peptide "works best" — it's a map of which claims are backed by what kind of evidence.
The comparison ledger
| Dimension | Ipamorelin | KPV | MOTS-c | Tirzepatide |
|---|---|---|---|---|
| Class | Selective growth-hormone secretagogue (ghrelin-receptor agonist) | Melanocortin-derived anti-inflammatory tripeptide | Mitochondrial-derived signaling peptide | Dual GIP/GLP-1 receptor agonist |
| Most-studied in | Postoperative gut recovery; body-weight preservation in a chemo model | Murine colitis; corneal wound healing | Muscle metabolism, exercise performance, mortality risk (mice + one human cohort) | Type 2 diabetes, obesity, sleep apnea |
| Human trial status | One published RCT, primary endpoint not met [3] | None published | None interventional; one observational cohort [14] | Multiple Phase 3 RCTs; FDA-approved [19][21][22] |
| Strongest evidence | Founding receptor-selectivity study in animals [5] | Repeated murine colitis benefit across independent labs [8][9] | Direct CK2 binding + aged-mouse performance gain [13][16] | Head-to-head superiority trial vs. an established comparator [18] |
| Best-documented open question | Long-term cardiovascular safety, borrowed from a related compound, not itself [2] | Any human pharmacokinetic or efficacy data at all | Human dose-response; ancestry/genotype variation | Lean-mass loss; gallbladder/biliary risk [20] |
Mechanism, side by side
The four compounds work through genuinely different biology, which is part of why they belong on one desk rather than four separate ones. Ipamorelin triggers a single hormone pulse by activating the ghrelin receptor on the pituitary [5]. KPV works locally in tissue, entering cells through a dedicated transporter and quieting two of the body's central inflammatory switches, NF-kB and MAP-kinase signaling [8]. MOTS-c operates inside the cell's own energy metabolism, nudging a fuel-sensing enzyme called AMPK and, under stress, physically relocating to the nucleus to help turn on protective genes [17]. Tirzepatide activates two separate hormone receptors on the outside of cells throughout the body, coordinating insulin release, digestion speed, and appetite all at once [19]. No two of these mechanisms overlap in a way that would let a reader generalize a finding from one compound to another.
How much evidence stands behind each claim
This is where the four separate most sharply. Tirzepatide's evidence base includes thousands of trial participants across multiple large, randomized, placebo- or active-comparator-controlled studies, plus years of post-market safety reporting [18][19][20][21][22]. KPV's evidence base, by contrast, is entirely preclinical — real, repeated, and mechanistically coherent, but confined to cell cultures and animal models with no human confirmation yet [6][7][8][9][10][11][12]. Ipamorelin sits in between: a well-characterized animal mechanism plus exactly one human trial, which did not meet its primary goal [3][5]. MOTS-c is its own unusual case — strong animal mechanistic and performance data, one meaningful human association study, and zero interventional human trials [13][14][16][17].
What's still missing from each file
Every compound on this desk has a documented gap, and naming it plainly is the whole point of reading research this way rather than taking a headline at face value. Ipamorelin's long-term cardiovascular safety data comes from a different peptide in its drug class, not from ipamorelin itself [2]. KPV has no human pharmacokinetic data of any kind — nobody has published what happens when a person, rather than a mouse, is given the compound. MOTS-c has no established human dosing, no measured human half-life, and a documented genetic variant that appears to change how people respond to it. Tirzepatide's gaps are narrower but real: a consistently documented gallbladder and biliary disease signal, and open questions about the roughly one-quarter of trial weight loss that came from lean muscle rather than fat [20].